XCancer

99mTc-PSMA-I&S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation

Description:

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

Sponsor:

Jonsson Comprehensive Cancer Center (UCLA)

Phase:

Early Phase 1

Contacts:

Maria Contreras (Clinical Research Coordinator)

mmcontreras@mednet.ucla.edu

310-825-7336

Government Study Link:

NCT04857502 - Click here to see study on

ClinicalTrials.gov

Isotope(s):
Target(s):
  • PSMA
Inclusion
  • Men who received a 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) for staging or restaging
  • Men who are scheduled for pelvic LN dissection (PLND)
  • Men who can provide oral and written informed consent
  • Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET/CT
  • Men with PCa (primary or recurrent disease)
Exclusion
  • Patients who started any PCa treatment between study enrollment and surgery
  • Technically inaccessible nodal location

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...